Gilead stock faces potential hit if Biktarvy is Trump’s price cut target
NegativeFinancial Markets
Gilead Sciences is facing potential challenges as its stock may be impacted if Biktarvy, a key HIV treatment, becomes a target for price cuts proposed by former President Trump. This situation is significant because it highlights the ongoing debate over drug pricing in the U.S. and could affect access to essential medications for patients.
— Curated by the World Pulse Now AI Editorial System